News
CSTL
24.84
-0.84%
-0.21
Weekly Report: what happened at CSTL last week (0330-0403)?
Weekly Report · 2h ago
Castle Biosciences CEO Derek Maetzold disposes of $0.06 million common shares
Reuters · 6d ago
Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside
Seeking Alpha · 6d ago
Weekly Report: what happened at CSTL last week (0323-0327)?
Weekly Report · 03/30 09:54
Castle Biosciences to present new data from DecisionDx-Melanoma test at AAD
TipRanks · 03/27 13:11
Castle Biosciences To Present New Data Showing DecisionDx-Melanoma Test Refines Mortality Risk Within AJCC Stages For Patients With Cutaneous Melanoma At 2026 AAD Annual Meeting
Benzinga · 03/27 13:08
Castle Biosciences shares rise; DecisionDx-Melanoma study in 1,868 SEER-linked patients shows 5-year melanoma-specific survival of 96.7% for Class 1A vs 70.0% for Class 2B in T1 tumors
Reuters · 03/27 13:07
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
PR Newswire · 03/27 13:05
Weekly Report: what happened at CSTL last week (0316-0320)?
Weekly Report · 03/23 09:51
Castle Biosciences CEO Derek J. Maetzold disposes of USD 500,438 in common shares
Reuters · 03/19 20:22
Castle Biosciences CEO Derek J. Maetzold disposes of USD 784,000 in common shares
Reuters · 03/17 20:38
Castle Biosciences Chief Commercial Officer Juvenal Tobin W disposes of USD 526,000 in common shares
Reuters · 03/16 20:08
Weekly Report: what happened at CSTL last week (0309-0313)?
Weekly Report · 03/16 09:51
Castle Biosciences CEO Derek J. Maetzold Disposes of Common Shares
Reuters · 03/13 20:11
Castle announces publication of DecisionDx-Melanoma’s i31-SLNB study results
TipRanks · 03/13 15:10
Castle Biosciences study links DecisionDx-Melanoma i31-SLNB low-risk result to 3% sentinel node positivity and 98% three-year recurrence-free survival
Reuters · 03/13 15:02
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
Barchart · 03/13 10:02
SciBase Q4 net sales rose 45% to SEK 12.48 million
Reuters · 03/13 07:18
Insider Move at Castle Biosciences Sparks Fresh Investor Buzz
TipRanks · 03/10 02:03
Castle Biosciences' i31‑SLNB Test Validates Predictive Accuracy In Melanoma Study, Supports Safe SLNB Avoidance
Benzinga · 03/09 11:12
More
Webull provides a variety of real-time CSTL stock news. You can receive the latest news about Castle Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About CSTL
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.